These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
476 related articles for article (PubMed ID: 26861867)
1. Risk factors for COPD exacerbations in inhaled medication users: the COPDGene study biannual longitudinal follow-up prospective cohort. Busch R; Han MK; Bowler RP; Dransfield MT; Wells JM; Regan EA; Hersh CP; BMC Pulm Med; 2016 Feb; 16():28. PubMed ID: 26861867 [TBL] [Abstract][Full Text] [Related]
2. Combination inhaled steroid and long-acting beta₂-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Rojas-Reyes MX; García Morales OM; Dennis RJ; Karner C Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD008532. PubMed ID: 27271056 [TBL] [Abstract][Full Text] [Related]
3. Effectiveness and Safety of COPD Maintenance Therapy with Tiotropium/Olodaterol versus LABA/ICS in a US Claims Database. Quint JK; Montonen J; Esposito DB; He X; Koerner L; Wallace L; de la Hoz A; Miravitlles M Adv Ther; 2021 May; 38(5):2249-2270. PubMed ID: 33721209 [TBL] [Abstract][Full Text] [Related]
4. Role of Tiotropium in Reducing Exacerbations of Chronic Obstructive Pulmonary Disease When Combined With Long-Acting β Ferroni E; Belleudi V; Cascini S; Di Martino M; Kirchmayer U; Pistelli R; Patorno E; Formoso G; Fusco D; Perucci CA; Davoli M; Agabiti N; J Clin Pharmacol; 2016 Nov; 56(11):1423-1432. PubMed ID: 27095425 [TBL] [Abstract][Full Text] [Related]
5. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease. Farne HA; Cates CJ Cochrane Database Syst Rev; 2015 Oct; (10):CD008989. PubMed ID: 26490945 [TBL] [Abstract][Full Text] [Related]
6. Outcomes associated with tiotropium use in patients with chronic obstructive pulmonary disease. Lee TA; Wilke C; Joo M; Stroupe KT; Krishnan JA; Schumock GT; Pickard AS Arch Intern Med; 2009 Aug; 169(15):1403-10. PubMed ID: 19667304 [TBL] [Abstract][Full Text] [Related]
7. Add-on tiotropium versus step-up inhaled corticosteroid plus long-acting beta-2-agonist in real-world patients with asthma. Chipps B; Mosnaim G; Mathur SK; Shaikh A; Khoury S; Gopalan G; Palli SR; Lamerato L; Casciano J; Dotiwala Z; Settipane R Allergy Asthma Proc; 2020 Jul; 41(4):248-255. PubMed ID: 32414426 [No Abstract] [Full Text] [Related]
9. Cost-effectiveness of the fixed-dose combination tiotropium/olodaterol versus tiotropium monotherapy or a fixed-dose combination of long-acting β2-agonist/inhaled corticosteroid for COPD in Finland, Sweden and the Netherlands: a model-based study. Hoogendoorn M; Corro Ramos I; Soulard S; Cook J; Soini E; Paulsson E; Rutten-van Mölken M BMJ Open; 2021 Aug; 11(8):e049675. PubMed ID: 34348953 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859 [TBL] [Abstract][Full Text] [Related]
11. Effects of inhaled corticosteroids in monotherapy or combined with long-acting {beta}2-agonists on mortality among patients with chronic obstructive pulmonary disease. Cyr MC; Beauchesne MF; Lemière C; Aaron SD; Blais L Ann Pharmacother; 2010 Apr; 44(4):613-22. PubMed ID: 20233915 [TBL] [Abstract][Full Text] [Related]
12. Current evidence for COPD management with dual long-acting muscarinic antagonist/long-acting β Skolnik NS; Nguyen TS; Shrestha A; Ray R; Corbridge TC; Brunton SA Postgrad Med; 2020 Mar; 132(2):198-205. PubMed ID: 31900019 [TBL] [Abstract][Full Text] [Related]
13. The impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting β-agonist therapy in COPD. Short PM; Williamson PA; Elder DHJ; Lipworth SIW; Schembri S; Lipworth BJ Chest; 2012 Jan; 141(1):81-86. PubMed ID: 21799028 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of revefenacin for nebulization in patients with chronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA: subgroup analysis from phase III trials. Sethi S; Donohue JF; Ferguson GT; Barnes CN; Crater GD Ther Adv Respir Dis; 2020; 14():1753466620905278. PubMed ID: 32106777 [TBL] [Abstract][Full Text] [Related]
15. Benefits and risks of adjunctive inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Sobieraj DM; White CM; Coleman CI Clin Ther; 2008 Aug; 30(8):1416-25. PubMed ID: 18803985 [TBL] [Abstract][Full Text] [Related]
16. The Effect on Total Mortality of Adding Inhaled Corticosteroids to Long-Acting Bronchodilators for COPD: A Real Practice Analysis in Italy. Di Martino M; Agabiti N; Cascini S; Kirchmayer U; Bauleo L; Fusco D; Belleudi V; Pinnarelli L; Voci C; Patorno E; Pistelli R; Davoli M; COPD; 2016 Jun; 13(3):293-302. PubMed ID: 26514912 [TBL] [Abstract][Full Text] [Related]
17. Comparative Effectiveness of Long-Acting Beta Samp JC; Joo MJ; Schumock GT; Calip GS; Pickard AS; Lee TA Pharmacotherapy; 2017 Apr; 37(4):447-455. PubMed ID: 28226405 [TBL] [Abstract][Full Text] [Related]
18. Comparative safety and effectiveness of inhaled bronchodilators and corticosteroids for treating asthma-COPD overlap: a systematic review and meta-analysis. Amegadzie JE; Gorgui J; Acheampong L; Gamble JM; Farrell J; Gao Z J Asthma; 2021 Mar; 58(3):344-359. PubMed ID: 31668101 [TBL] [Abstract][Full Text] [Related]
19. Long-acting Muscarinic Antagonist Versus Inhaled Corticosteroid when Added to Long-acting β-agonist for COPD: A Meta-analysis. Oba Y; Chandran AV; Devasahayam JV COPD; 2016 Dec; 13(6):677-685. PubMed ID: 27148815 [TBL] [Abstract][Full Text] [Related]